Agreed. Including bonus issue, the return in Texofab is 10x. i.e. Anyone who’d have invested 1lac in Texofab IPO in 2017 would be sitting on 10lacs as of now. Peaked to 15lacs few months back.
16.1. lokes| Link| Bookmark|
October 1, 2022 10:46:03 PM
IPO Guru (4400+ Posts, 5100+ Likes)
i am getting feeling that it will list at par....around 100-102 mostly..... and then it may lock in UC due to low selling pressure from retailers and if HNI's are genuine here means if no fake subscription....Well i may be wrong too as anything can happen in sme's.... Even PE is high at issue price but company financials both revenue and profits are growing every year and it has good presence in international markets too. It has some subscription from FII's too as per BSE site data... https://www.bseindia.com/markets/publicIssues/BSEDemandSchedule_FPO.aspx?Scripcode=5883&status=L
16.2. Kapz| Link| Bookmark|
October 2, 2022 10:24:41 AM
IPO Mentor (800+ Posts, 400+ Likes)
Besides that, promoters seem to have a good track record. Hardik J Desai And Chetan C Jariwala (Rupaben C Jariwala‘s husband) are also promoters of Trident Texofab whose IPO came in 2017. Issue price was 30, got listed at 68 and earlier this year rose to 200. Currently trading at 126.50.
16.3. Kapz| Link| Bookmark|
October 2, 2022 10:32:02 AM
IPO Mentor (800+ Posts, 400+ Likes)
In 2020, issued bonus shares of 14:10, so the real value addition will be more than what’s reflected in the current price.
16.4. lokes| Link| Bookmark|
October 10, 2022 12:08:17 PM
IPO Guru (4400+ Posts, 5100+ Likes)
As informed in my above post here, it has done well and locked in UC too...
@lokes, @mravi, @pkraj, @avenue, @ipobull, @monsterzero, @mehulstk, other Experts and Veterans - So what happens, or rather what are the options, when the IPO is undersubscribed? If I remember correctly, there were a couple of IPOs around 2-3 months back which were undersubscribed and basically they were extended by a couple of days with reduced price. Is it what the common practice is or are there any other possible outcomes too?
The underwriter needs to buy all the remaining unsold quality. This is what we where taught in college in B.com course. The underwriter charges commission for ensuring subscription in an IPO.
@SunilP, thanks. Am I right in guessing that would happen only if under subscription is marginal or nominal i.e. close to 85-90%? As we can see, it was way under subscribed for Maagh and they just extended the date. Will be interesting to see if this extension does anything much or not. If not, what happens next.
I suppose, having too many concurrent IPOs has actually made it easier for everyone to leave out the really bad ones. If IPOs like Maagh and QMS would have come on their own, they may have still gotten fully subscribed, which may not have been ideal. I may be wrong in that assumption, but just a thought.